Navigation Links
Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
Date:10/22/2007

NCE V versus TAXUS in Europe and Asia Pacific, in which XIENCE V demonstrated superiority in the primary endpoint of in-stent late loss at 6 months, and clinical superiority on MACE with a 71 percent reduction compared to TAXUS at one year.

SPIRIT III is a large-scale pivotal clinical trial comparing XIENCE V to TAXUS in the United States and Japan that demonstrated superiority to TAXUS in the on the study's primary endpoint of in-segment late loss at eight months with a statistically significant 50 percent reduction in late loss compared to TAXUS.

Abbott's robust post-approval program is projected to enroll over 13,000 XIENCE V patients across a variety of planned clinical trials. SPIRIT IV is a 3,690-patient continued access trial that is currently enrolling patients and will evaluate the safety and efficacy of XIENCE V for the treatment of coronary artery disease in a more complex patient population in the United States. SPIRIT V is an international clinical trial that will provide additional clinical experience with XIENCE V in approximately 3,000 patients at approximately 100 clinical sites throughout Europe, Asia, Canada and Latin America. XIENCE V SPIRIT WOMEN is the world's first drug eluting stent trial to study only women and will evaluate the characteristics of 2,000 women undergoing stent implantation as well as the performance of XIENCE V in those patients in Europe, Asia-Pacific, Canada and Latin America. XIENCE V USA is a post-approval trial planned for the US with 5,000 patients.

For images of Abbott's XIENCE V stent and other information, please visit the company's online TCT newsroom at http://www.abbottvascular.com/presskit.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by c
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
2. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
3. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
4. Efficacy of OrbusNeichs Genous Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents
5. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
6. Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial Results at EuroPCR 2007
7. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
8. Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR
9. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
10. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
11. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...
(Date:6/19/2013)... 19, 2013   Nektar Therapeutics (Nasdaq: ... abuse liability (HAL) study for NKTR-181, a first-in-class, ... the brain.  This slow rate of entry is designed to ... and addiction to current opioid analgesics. 1 In the ... similar to placebo in "drug liking" and "feeling high" scores ...
(Date:6/19/2013)... SAN JOSE, Calif. , June 19, 2013 ... (NYSE: BDX ), a leading global medical technology ... X-20 Cell Analyzer , the latest in its line of ... X-20 Cell Analyzer delivers high-performance multicolor analysis with the most ... (76.2 X 73.7 cm) and a height of 30" (76.2 ...
Breaking Medicine Technology:Drug Patent Watch 2Drug Patent Watch 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2
(Date:6/19/2013)... 19, 2013 The benefits, NASS ... sauna but the overall experience for the majority of ... health-wise. , Mr Mouw, whose Virgina-based company enjoys an ... statement by saying that the type of sauna is ... number of counterfeit imitations which frankly, can be extremely ...
(Date:6/19/2013)... 2013 Across the globe billions of ... access to the medical advances that benefit developed western ... health care and the necessary aid to help curb ... , Outlook with Ben Kingsley is partnering ... in which these people live and highlight the invaluable ...
(Date:6/19/2013)... Denver, Colorado (PRWEB) June 19, 2013 Daily ... vertical jump training method will be published on ... a preview of the article to inform readers about the ... the declaration made by reporters working at Daily Gossip, the ... Manual Guide . , Hiller has understood during the ...
(Date:6/19/2013)... Are you using Twitter in your marketing campaigns? ... , Social media marketing is a proven and affordable ... Included in your social media campaigns should be Twitter messaging, ... and revenue for your business. , According to Statistic ... Many of these individuals are not just using the service ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Researchers from ... demonstrated several new studies at ENDO 2013, ... from June 15-18 in San Francisco.     , Mount Sinai ... as the role of prostastic acid phosphatase (PAP) in ... can stimulate the thyroid gland; revealed the prevalence of ...
Breaking Medicine News(10 mins):Health News:Health Benefits of Saunas Only Viable with Properly Constructed Models, Warns Manufacturer 2Health News:The Jump Manual Review: Reveals Hiller’s Method of Vertical Jump Training 2Health News:If Your Massage Practice Isn’t Tweeting, It Isn’t Generating New Sales: 3 Ways Twitter Helps Grow Massage Practices from Appointment-Plus 2Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 2Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 3Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 4Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 5Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 6Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 7
... Scientists know little about how the brain creates and ... obstacle in the effort to develop treatments for emotional ... is in its infancy," says Howard Hughes Medical Institute ... continue to take an enormous toll on human society." ...
... heart risk, leaked documents suggest , SATURDAY, Feb. 20 ... Avandia raises users, odds for heart attack and heart ... to confidential government reports. , The New York ... U.S. Food and Drug Administration that find that if ...
... ... it,s new shop in Beverly Hills, featuring old style barbering, straight razor shaves, in a ... ... today the official opening of its Beverly Hills store located at 9635 Brighton Way, Beverly ...
... ... chief loss mitigator for IndyMac Banks HELOC division, conducted a short sale continuing ... Honish is the first bank employee approved by any state to conduct a ... only course on the subject of short sales taught from this perspective. The ...
... ... ... , ... , ...
... ... ... ... , ...
Cached Medicine News:Health News:David Anderson to discuss what model organisms can teach us about emotion 2Health News:Remove Diabetes Drug Avandia From Market: FDA Reports 2Health News:Remove Diabetes Drug Avandia From Market: FDA Reports 3Health News:Remove Diabetes Drug Avandia From Market: FDA Reports 4Health News:The Classic Shave Company Announces the Opening of Beverly Hills Shop 2Health News:Former Bank Negotiator Turns On Bank and is Approved by the Department of Real Estate 2Health News:Former Bank Negotiator Turns On Bank and is Approved by the Department of Real Estate 3Health News:California Dental Association Foundation Expands Care to State's Underserved Communities 2Health News:California Dental Association Foundation Expands Care to State's Underserved Communities 3Health News:California Dental Association Foundation Expands Care to State's Underserved Communities 4Health News:California Dental Association Foundation Expands Care to State's Underserved Communities 5Health News:WebMD to Present at the Goldman Sachs Technology and Internet Conference 2010 2Health News:WebMD to Present at the Goldman Sachs Technology and Internet Conference 2010 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: